Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Filed with HKEX · Stock code 6978 · · 10 pages · English
Summary by 6ix AI
It confirms that the total authorized share capital remains unchanged at the end of the month. The report also states that there were no changes in the number of issued shares or treasury shares during the month. Additionally, it includes confirmations regarding compliance with listing rules and regulatory requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Immunotech Biopharm Ltd on 6ix
Earlier from Immunotech Biopharm
- Supplemental announcement to the annual report for the year ended 31 December 2025
- 2026 Interim report
- Major transaction further delay in despatch of circular in relation to the construction of the new biological drug R&D and industrialisation based in beijing
- Change of senior management
- Immunotech Biopharm: Major transaction construction agreement in relation to the construction of the new biological drug R&D and industrialisation base in beijing
Follow Immunotech Biopharm into a list and get an email when it puts out news.
Follow Immunotech Biopharm